Hospira (United States) holds 2 active US FDA Type II Drug Master Files and 13 inactive, has DMF or CEP filings on record for 4 active ingredients and is linked to 3 FDA-registered manufacturing sites. 50 FDA enforcement records are linked to it.
Sources: FDA Drug Master File list, EDQM certification database, FDA establishment registrations and enforcement records. How we read these records
Cite as: PharmaTek, “Hospira: DMF, site and FDA enforcement record”, record as of 16 Nov 2026, pharmatek.co.uk/directory/hospira
Overview
Hospira is a subsidiary of Pfizer Inc., specializing in injectable drugs and infusion technologies. The company is known for its development and manufacturing of high-quality biosimilars and generic injectables.
Therapeutic areas
Active ingredients with DMF or CEP filings
Substances for which Hospira holds, or has held, a US FDA Drug Master File or an EU CEP. A filing is not proof of current supply. Open any ingredient to see all its holders, CAS number and product patent dates.
API / Drug Master Files
Hospira holds 2 active (15 total) FDA Type II Drug Master Files. A Type II DMF is filed with the FDA to support an active ingredient in drug applications; an active filing can be referenced but is not proof of current supply, and inactive filings are historical.
- ISOPROTERENOL HYDROCHLORIDE DRUG SUBSTANCEActive2011-08-16
- VANCOMYCIN HYDROCHLORIDEActive1998-09-01
- NT100H DRUG SUBSTANCEInactive2012-09-28
- OXALIPLATIN DRUG SUBSTANCEInactive2010-11-15
- PAMIDRONIC ACID DRUG SUBSTANCEInactive2006-07-03
- ATHERO GENICS AGIX-4207 INJECTABLE EMULSIONInactive2001-08-15
- OFNE ADMIXTURE DRUG PRODUCTSInactive2000-04-28
- ROGOSIN EMULSIONInactive1999-06-28
- TEQUIN I.V. (GATIFLOXACIN)Inactive1998-12-21
- LAMISIL EMULSIONInactive1998-01-29
- CLEVIDIPINE EMULSIONInactive1995-02-23
- SPC-100270 EMULSIONInactive1992-12-16
- PFC EMULSIONInactive1992-11-17
- TIN ETHYL ETIOPURPURIN (TEP) EMULSION PROCESSING IN KUNGSANGEN AND STOCKHOLM, SWEDENInactive1992-06-29
- INTRAVENOUS FAT EMULSION PRODUCT 4501Inactive1987-10-05
Registered manufacturing sites (3)
Physical sites registered with the US FDA and resolved to Hospira, with any EU/UK GMP documents matched to each site. Headquarters and manufacturing locations can differ.
FDA compliance signals
50 FDA enforcement records linked to this company.
- 4832025-01-17
Procedures for sterile drug products
- 4832025-01-17
Control procedures to monitor and validate performance
- 4832025-01-17
Investigations of discrepancies, failures
- 4832020-01-17
Acceptance criteria for sampling & testing
- 4832020-01-17
Validation lacking for sterile drug products
- 4832020-01-17
Investigations of discrepancies, failures
- 4832020-01-17
Procedures not in writing, fully followed
- 4832020-01-17
Complete instructions, procedures, specifications et. al.
- 4832020-01-17
SOPs not followed / documented
- 4832020-01-17
Written record of investigation incomplete
- 4832020-01-17
Exhaust systems inadequate to control air contamination
- 4832020-01-17
In-process conformity - examination, sample testing
- 4832020-01-17
Control procedures to monitor and validate performance
- 4832019-11-21
Written record of investigation incomplete
- 4832019-11-21
Scientifically sound laboratory controls
- 4832019-11-21
Investigations of discrepancies, failures
- 4832018-02-02
Test devices not meeting specifications
- 4832018-02-02
Calibration/Inspection/Checking not done
- 4832018-02-02
Procedure Deviations Recorded and Justified
- recall — Class I2017-05-31
Presence of Particulate Matter: human hair found within an internal sample syringe.
- warning_letter2017-02-14
FDA Warning Letter (drug product)
- recall — Class III2016-12-14
Failed Stability Specifications: The recalled lots did not meet the specification for color and pH throughout shelf life.
- recall — Class II2016-11-30
Lack of Assurance of Sterility: Complaints of broken tips on the ampules.
- recall — Class II2016-09-21
Discoloration: Firm received complaints of product discoloration and particulates.
- recall — Class II2016-07-20
Crystallization: Product contains particulate identified to be crystallized active ingredient.
- recall — Class I2016-07-13
Presence of Particulate Matter: Confirmed customer complaint for the presence of particulate matter.
- recall — Class II2016-06-22
Presence of Particulate Matter: Cardboard
- recall — Class I2016-06-01
Presence of Particulate Matter: particulate matter identified as an insect in one vial.
- recall — Class III2016-05-25
Failed pH Specifications: Confirmed high out of specification (OOS) results for pH.
- recall — Class III2016-05-11
Labeling: Incorrect or Missing Lot and/or Exp Date: Potential for the lot number and/or expiration date to be faded or missing from the primary label on the glass vial.
- recall — Class II2016-04-27
Chemical Contamination: Potential for contamination of the products with an aromatic hydrocarbon resin.
- recall — Class II2016-04-27
Chemical Contamination: Potential for contamination of the products with an aromatic hydrocarbon resin.
- recall — Class II2016-04-27
Chemical Contamination: Potential for contamination of the products with an aromatic hydrocarbon resin.
- recall — Class II2016-04-27
Chemical Contamination: Potential for contamination of the products with an aromatic hydrocarbon resin.
- recall — Class II2016-04-27
Chemical Contamination: Potential for contamination of the products with an aromatic hydrocarbon resin.
- recall — Class II2016-04-27
Chemical Contamination: Potential for contamination of the products with an aromatic hydrocarbon resin.
- recall — Class III2016-03-02
Labeling: Incorrect or Missing Lot and/or Exp Date: Confirmed customer report of an incorrect expiration date printed on the primary container labeled "01AUG1017" rather than "01AUG2017".
- recall — Class I2016-02-24
Labeling: Incorrect Barcode: Primary bag labeling may be mislabeled with the wrong barcode which scans in as heparin sodium.
- recall — Class III2015-10-28
Failed Impurities/Degradation Specifications: Out of Specification(OOS) results for degradation product of etomidate was confirmed during stability testing.
- recall — Class II2015-09-30
Presence of Particulate Matter: particulate matter identified as iron oxide, was found embedded in the neck of glass vials.
- recall — Class II2015-09-23
Defective Container: There were customer complaints of cracked and leaking glass vials.
- recall — Class II2015-07-22
Crystallization; identified as calcium salt of Ketorolac
- recall — Class II2015-07-22
Crystallization; identified as calcium salt of Ketorolac
- recall — Class II2015-07-22
Lack of assurance of sterility: Potential channel leaks near the threaded vial port.
- recall — Class I2015-07-15
Presence of Particulate Matter: Presence of free-floating and embedded iron oxide particles.
- recall — Class III2015-07-15
Failed pH Specifications: 12 month stability testing
- recall — Class I2015-06-03
Non-Sterility: Confirmed customer report of dark, fibrous particulates floating within the solution of the primary container, which were subsequently identified as mold
- recall — Class I2015-05-20
Labeling: Wrong Bar Code: There is a potential for some units to be mislabeled with an incorrect barcode on the immediate container that scans as heparin sodium 2000 USP units/1000 mL in 0.9% in sodium chloride injection.
- recall — Class I2015-05-13
Presence of Particulate Matter: Confirmed finding of human hair floating in IV solution.
- recall — Class II2015-05-06
Crystallization
Is this Hospira?
Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.
Related companies
Need suppliers found and checked?
The Sourcing Desk turns these records into a checked shortlist: current filings, site, grade and regulatory history confirmed for your product, for a buyer-paid fixed fee and no supplier commission.